Atara Biotherapeutics (NASDAQ:ATRA) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?Defense World · Oct 17, 2026
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug AdministrationBusiness Wire · Oct 14, 2026
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)Defense World · Oct 12, 2026
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug AdministrationGuruFocus · Sep 30, 2026
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug AdministrationBusiness Wire · Sep 30, 2026
Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)Defense World · Sep 21, 2026Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.32 | -$0.32 | Miss |
| May 14, 2026 | -$0.33 | -$0.29 | Beat |
| Mar 16, 2026 | -$0.09 | -$0.25 | Miss |
| Nov 12, 2025 | -$0.83 | -$0.32 | Beat |
| Aug 11, 2025 | -$0.32 | $0.19 | Beat |
| May 15, 2025 | -$3.07 | $3.50 | Beat |